Endpoints News 2. Apr. 2026 Novo and Lilly battle over GLP-1 claims only a head-to-head trial can answer
Endpoints News 2. Apr. 2026 Eli Lilly's chief technology officer retires after 35 years; Astellas strategy exec resigns
Endpoints News 1. Apr. 2026 Lilly wins approval of anti-obesity pill orforglipron, setting up new battle with Novo
Endpoints News 20. März 2026 UK’s NICE revisits Lilly, Eisai Alzheimer's drugs under new pricing threshold
Endpoints News 19. März 2026 Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggest
Endpoints News 12. März 2026 Lilly warns of impurity risk in certain compounded forms of Mounjaro and Zepbound
Endpoints News 11. März 2026 Lilly plots GLP-1 pill production boost in China, $500M pledge to South Korea
Endpoints News 6. März 2026 Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president
Endpoints News 26. Feb. 2026 Lilly's GLP-1 pill beats Novo’s in diabetes trial, has more side effects
Endpoints News 24. Feb. 2026 Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
Endpoints News 23. Feb. 2026 Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial